secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caribou Biosciences, Inc. (CRBU)
CIK:        0001619856
Form:       8-K
Filed at:   2023-12-22T23:59:59+00:00
Accession:  0001619856-23-000138
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caribou Biosciences CMO Syed Rizvi to leave Dec 31, 2023; severance terms set
-----------------------------------------------------------------------------

- Dr. Rizvi's departure effective Dec 31, 2023; previously announced Dec 12, 2023.
- Separation agreement provides 9 months base salary and COBRA premium reimbursement.
- 15,000 RSUs will vest on Jan 18, 2024 as originally scheduled.
- Post-termination exercise period for vested options extended through June 30, 2024.
- No successor named; bonus for 2023 at board discretion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1619856/000161985623000138/0001619856-23-000138-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1619856/000161985623000138/crbu-20231222.htm
  HTML page:      https://secwatch.observer/filing/0001619856-23-000138

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer